+

WO2006030211A2 - Sulfamides acycliques - Google Patents

Sulfamides acycliques Download PDF

Info

Publication number
WO2006030211A2
WO2006030211A2 PCT/GB2005/003551 GB2005003551W WO2006030211A2 WO 2006030211 A2 WO2006030211 A2 WO 2006030211A2 GB 2005003551 W GB2005003551 W GB 2005003551W WO 2006030211 A2 WO2006030211 A2 WO 2006030211A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
methyl
substituents
moiety
amino
Prior art date
Application number
PCT/GB2005/003551
Other languages
English (en)
Other versions
WO2006030211A3 (fr
Inventor
Christopher John Hobbs
Rosemary Lynch
Sarah Louise Mellor
Fleur Radford
Jenny Christine Gilbert
Stephen Stokes
Angela Glen
Andrea Fuimana
Christopher Geoffrey Earnshaw
Lars Jacob Stray Knutsen
Kathryn Elizabeth Sorrel Dean
Original Assignee
Vernalis (R & D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis (R & D) Limited filed Critical Vernalis (R & D) Limited
Publication of WO2006030211A2 publication Critical patent/WO2006030211A2/fr
Publication of WO2006030211A3 publication Critical patent/WO2006030211A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Definitions

  • the present invention relates to specific benzenesulfonamide derivatives which act as inhibitors of N-type calcium channels.
  • Mammalian ion channels are becoming increasingly well characterised, and this is especially true of calcium channels.
  • Voltage-gated calcium channels are critical components for the functioning of the nervous system, and they signal a painful event.
  • 7 subtypes of these channels have been identified (L, N, T, O, P, Q and R), each expressed in various combinations by neuronal and non-neuronal cells (Perez- Reyes, E.; Schneider, T. DrugDev. Res., 1994, 33, 295-318). These channels are now recognised as valid targets for pain therapeutics and as neuroprotective agents (Cox, B.; Denyer, J.C. Expert Opinion on Therapeutic Patents, 1998, 8, 1237-1250).
  • A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6- membered heterocyclyl group;
  • B is a bond or a C 1 -C 6 alkyl or C 2 -C 6 alkenyl moiety; either (a) R 1 is hydrogen or C 1 -C 6 alkyl and R 2 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, halogen, hydroxy, thio, amino, -Het-L or -L-Het-L', wherein L and L 1 are the same or different and represent C 1 -C 6 alkyl or C 2 -C 6 alkenyl and Het is O, S or NR, wherein R is hydrogen or C 1 -C 6 alkyl, or (b) R 1 and R 2 form, together with the carbon to which they are attached, a 5- to 10-membered heterocyclyl or a C 3 -C 8 carbocyclyl moiety;
  • R 3 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or -L-Het-L', wherein L, L' and Het are as defined above;
  • - R 4 , R 5 and R 6 are the same or different and represent hydrogen, halogen, hydroxy, amino, thio, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, HiOnO(C 1 -C 6 alkyl)amino or di(Ci-C 6 alkyl)amino;
  • the alkyl and alkenyl groups and moieties in B and R 1 to R 6 being unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, hydroxy, amino and thio substituents;
  • the heterocyclyl and carbocyclyl moieties formed by R 1 and R 2 being
  • a C 1 -C 6 alkyl group or moiety is a linear or branched alkyl group or moiety containing from 1 to 6 carbon atoms, such as a C 1 -C 4 alkyl group or moiety, for example methyl, ethyl, «-propyl, /-propyl, R-butyl, /-butyl and /-butyl.
  • Preferred C 1 -C 6 alkyl groups include methyl, ethyl, /-propyl and /-butyl.
  • a divalent alkyl group or moiety can be attached via the same carbon atom, via adjacent carbon atoms or via non-adjacent carbon atoms.
  • Examples of divalent alkyl moieties are methylene and 1,1 -ethyl moieties.
  • a preferred divalent alkyl moiety is a 1,1 -ethyl moiety.
  • a C 2 -C 6 alkenyl group or moiety is a linear or branched alkenyl group or moiety containing from 2 to 6 carbon atoms, such as a C 2 -C 4 alkenyl group or moiety, for example ethenyl, n-propenyl and n-butenyl.
  • a preferred C 2 -C 6 alkenyl group is ethenyl.
  • an alkenyl group has only one double bond. This double bond is typically located at the V-position of the alkenyl group.
  • a divalent alkenyl group or moiety can be attached via the same carbon atom, via adjacent carbon atoms or via non-adjacent carbon atoms.
  • a halogen is typically chlorine, fluorine, bromine or iodine and is preferably chlorine, fluorine or bromine.
  • a said C 1 -C 6 alkoxy group is typically a said C 1 -C 6 alkyl group attached to an oxygen atom.
  • a said C 1 -C 6 alkylthio group is typically a said C 1 -C 6 alkyl group attached to a thio group.
  • a C 1 -C 6 haloalkyl group is typically a said C 1 -C 6 alkyl group, substituted by one or more said halogen atoms. Typically, it is substituted by 1 , 2 or 3 said halogen atoms.
  • haloalkyl groups include perhaloalkyl groups such as -CX 3 wherein X is a said halogen atom.
  • Preferred haloalkyl groups are fluoroalkyl groups such as -CF 3 and -CHF 2 .
  • a particularly preferred haloalkyl group is -CF 3 .
  • a C 1 -C 6 haloalkoxy group is typically a said C 1 -C 6 alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1 , 2 or 3 said halogen atoms.
  • Preferred haloalkoxy groups include perhaloalkoxy groups such as -OCX 3 wherein X is a said halogen atom.
  • a particularly preferred haloalkoxy group is -OCF 3 .
  • a C 1 -C 6 haloalkylthio group is typically a said C 1 -C 6 alkylthio group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
  • Preferred haloalkylthio groups include perhaloalkylthio groups such as -SCX 3 wherein X is a said halogen atom.
  • a particularly preferred haloalkylthio group is -SCF 3 .
  • a 5- to 10-membered heteroaryl group is typically a 5- to 10- membered monocyclic aromatic ring, such as a 5- or 6-membered ring, containing at least one heteroatom, for example 1 , 2 or 3 heteroatoms, selected from O, S and N.
  • heteroatoms for example 1 , 2 or 3 heteroatoms, selected from O, S and N.
  • Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazyl, thiazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl groups.
  • A represents a 5- to 10-membered heteroaryl moiety fused to a phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl group, it is preferably a 5- to 6-membered heteroaryl moiety fused to a phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl group.
  • A represents a 5- to 10-membered heteroaryl moiety fused to a cyclic group, it is preferably fused to a phenyl or pyridyl group.
  • fused groups include an oxazolyl moiety that is fused to a phenyl or pyridyl group to form a benzo[d] oxazolyl or oxazolopyridinyl group, respectively.
  • a C 3 -C 8 carbocyclyl group is a non-aromatic saturated or unsaturated hydrocarbon ring, having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms. Preferably it is a saturated hydrocarbon ring (i.e. a cycloalkyl group) or an unsaturated ring having only one double bond. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cyclopropyl and cyclohexyl groups are preferred.
  • a heterocyclyl group is typically a monocyclic, non-aromatic, saturated or unsaturated C 5 -C 10 carbocyclic ring, such as a C 5 -C 6 carbocyclic ring, in which one or more, for example 1, 2 or 3, of the carbon atoms are replaced by a moiety selected from N, O, S, SO and S(O) 2 .
  • said moiety is selected from N, O and S.
  • saturated heterocyclyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, dioxanyl, tetrahydrothiopyranyl, dithianyl, morpholinyl, thiomorpholinyl, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, dithiolanyl, thiazolidinyl and oxazolidinyl.
  • suitable unsaturated heterocyclic groups include dihydro-oxazolyl, dihydroisoxazyl, dihydrothiazolyl, dihydroisothiazolyl, dihydro-oxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydroimidazolyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl and dihydropyridazinyl.
  • Preferred unsaturated heterocyclic groups are dihydro-oxazolyl, dihydroisoxazyl, dihydrothiazolyl, dihydroisothiazolyl, dihydroimidazolyl and dihydropyrazolyl. Dihydro-oxazolyl is particularly preferred.
  • A represents a 5- to 10-membered heterocyclyl moiety fused to a phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl group
  • it is preferably a 5- to 6-membered heterocyclyl moiety, and more preferably an unsaturated 5- to 6-membered heterocyclyl moiety, fused to a phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl group.
  • A represents a 5- to 10-membered heterocyclyl moiety fused to a cyclic group, it is preferably fused to a phenyl or pyridyl group.
  • A represents a 5- to 10-membered heterocyclyl moiety fused to a cyclic group, it is preferably fused to a phenyl or pyridyl group.
  • a compound of formula (I) contains more than one L, L 1 or Het moiety, each of the respective moieties is the same or different.
  • R in the or each Het moiety is hydrogen or C 1 -C 4 alkyl.
  • R in the or each Het moiety is hydrogen or methyl.
  • L in the or each R 1 , R 3 or A moiety is C 1 -C 4 alkyl.
  • L in the or each R 1 , R 3 or A moiety is C 1 -C 2 alkyl.
  • L 1 in the or each R 1 , R 3 or A moiety is C 1 -C 4 alkyl.
  • L 1 in the or each R 1 , R 3 or A moiety is C 1 -C 2 alkyl.
  • Het is O, S or NR, wherein R is as defined above.
  • Het is O.
  • the alkyl and alkenyl groups and moieties in B and R 1 to R 6 are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from fluorine, chlorine, bromine or hydroxy substituents.
  • the alkyl and alkenyl groups and moieties in B and R 1 to R 3 are unsubstituted or substituted by a single hydroxy substituent.
  • the alkyl and alkenyl groups and moieties in R 4 to R 6 are unsubstituted or substituted by one, two or three fluorine or chlorine substituents.
  • the heterocyclyl and carbocyclyl moieties formed by R 1 and R 2 are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from fluorine, chlorine, bromine or hydroxy substituents.
  • the heterocyclyl and carbocyclyl moieties formed by R 1 and R 2 are unsubstituted.
  • the group A is substituted, only one of the substituents is a group selected from phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6- membered heterocyclyl.
  • the group A is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, -L-Het-L', phenyl, 5- to 6-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 6- membered heterocyclyl, wherein L, L 1 and Het are as defined above.
  • the group A is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from C 1 -C 6 alkyl, -(C 1 -C 2 alkyl)-O-(Ci-C 2 alkyl), cyclopropyl or phenyl.
  • alkyl and alkenyl moieties in the substituents on A are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from fluorine, chlorine, bromine and hydroxy substituents
  • the alkyl and alkenyl moieties in the substituents on A are unsubstituted or substituted by a single hydroxy substituent or by one, two or three fluorine or chlorine substituents.
  • the phenyl, heteroaryl, carbocyclyl and heterocyclyl substituents on A are unsubstituted or substituted by one, two or three futher unsubstituted substituents selected from fluorine, chlorine, bromine, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl and C 1 -C 4 haloalkoxy groups.
  • the phenyl, heteroaryl, carbocyclyl and heterocyclyl substituents on A are unsubstituted.
  • A is a 5- to 6-membered heteroaryl or heterocyclyl moiety, in particular a 5- to 6-membered heteroaryl or unsaturated heterocyclyl moiety, said moiety being optionally fused to a phenyl or 5- to 6-membered heteroaryl group.
  • A is a pyridyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl or dihydro-oxazolyl moiety, said moiety being optionally fused to a phenyl or pyridyl group.
  • A is a pyridyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, dihydro-oxazolyl, benzo[d] oxazolyl or oxazolopyridinyl moiety.
  • B is a bond or a C 1 -C 4 alkyl moiety.
  • B is a bond or a C 1 - C 2 alkyl moiety, for example a 1,1 -ethyl moiety.
  • R 1 is hydrogen or C 1 -C 4 alkyl.
  • R 1 is hydrogen or methyl.
  • R 2 is hydrogen or C 1 -C 6 alkyl.
  • R 2 is hydrogen or C 1 -C 4 alkyl. More preferably, R 2 is hydrogen or C 1 -C 4 alkyl group which is unsubstituted or substituted with a single hydroxy group.
  • R 1 and R 2 form, together with the carbon to which they are attached, a 5- to 10-membered heterocyclyl moiety or C 3 -Cg carbocyclyl moiety, they typically form a saturated 5- to 6-membered heterocyclyl moiety or a C 3 -C 6 carbocyclyl moiety. Preferably, they form a C 3 -C 6 carbocyclyl moiety such as a cyclopropyl or cyclohexyl moiety.
  • R 3 is hydrogen, C 1 -C 6 alkyl or -L-Het-L 1 , wherein L, L' and Het are as defined above.
  • R 3 is hydrogen, C 1 -C 4 alkyl or -(C 1 -C 2 alkyl)-O-(Ci-C 2 alkyl). More preferably, R 3 is hydrogen, an unsubstituted -(C 1 -C 2 alkyl)-O-(C 1 -C 2 alkyl) group or a C 1 -C 4 alkyl group which is unsubstituted or carries a single hydroxy substituent.
  • R 4 , R 5 and R 6 are the same or different and represent hydrogen, fluorine, chlorine, bromine, hydroxy, amino, thio, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, mono(C 1 -C 4 alkyl)amino or CIi(C 1 -C 4 alkyl)amino.
  • R 4 , R 5 and R 6 are the same or different and represent hydrogen, fluorine, chlorine, bromine or C 1 -C 2 alkyl.
  • R 4 , R 5 and R 6 are the same or different and represent hydrogen, fluorine, chlorine, bromine or an unsubstituted C 1 -C 2 alkyl or C 1 -C 2 haloalkyl group.
  • Preferred compounds of formula (I) are those wherein: A is a 5- to 6-membered heteroaryl or unsaturated heterocyclyl moiety, said moiety being optionally fused to a phenyl or 5- to 6-membered heteroaryl group;
  • B is a bond or a C 1 -C 4 alkyl moiety; - either (a) R 1 is hydrogen or C 1 -C 4 alkyl and R 2 is hydrogen or C 1 -C 6 alkyl or (b)
  • R 1 and R 2 form, together with the carbon to which they are attached, a saturated 5- to 6- membered heterocyclyl moiety or a C 3 -C 6 carbocyclyl moiety;
  • R 3 is hydrogen, C 1 -C 6 alkyl or -L-Het-L 1 , wherein L and L' are the same or different and represent C 1 -C 4 alkyl and Het is O, S or NR, wherein R is hydrogen or C 1 - C 4 alkyl;
  • R 4 , R 5 and R 6 are the same or different and represent hydrogen, fluorine, chlorine, bromine, hydroxy, amino, thio, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, mono(Ci-C 4 alkyl)amino or di(C 1 -C 4 alkyl)amino;
  • the alkyl groups and moieties in B and R 1 to R 6 being unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from fluorine, chlorine, bromine or hydroxy substituents;
  • A is a pyridyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, dihydro-oxazolyl, benzo [d ⁇ oxazolyl or oxazolopyridinyl moiety;
  • B is a bond or a C 1 -C 2 alkyl moiety; - either (a) R 1 is hydrogen or methyl and R 2 is hydrogen or C 1 -C 4 alkyl or (b) R 1 and R 2 form, together with the carbon to which they are attached, a C 3 -C 6 carbocyclyl moiety;
  • R 3 is hydrogen, C 1 -C 4 alkyl or -(C J -C 2 alkyl)-O-(C 1 -C 2 alkyl);
  • R 4 , R 5 and R 6 are the same or different and represent hydrogen, fluorine, chlorine, bromine or C 1 -C 2 alkyl;
  • the present invention further provides the use of a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prevention of a condition mediated by N-type calcium channels.
  • Examples of particularly preferred compounds of formula (I) are: 1. N-(5-tert-Butyl-[l ,3,4]oxadiazol-2-ylmethyl)-2-chloro-N-methyl-4-trifluoro- methylbenzenesulfonarnide; 2. 2-Chloro-N-methyl-N-(5-methyl-[l ,3,4]oxadiazol-2-ylmethyl)-4-trifluoromethyl- benzenesulfonamide;
  • a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
  • Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulfonic, ethanesulfonic, benzenesulfonic or p-toluenesulfonic acid.
  • Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g.
  • the compounds of the invention contain one or more chiral centre.
  • the chemical structures depicted herein are intended to embrace all stereoisomers of the compounds shown, including racemic and non-racemic mixtures and pure enantiomers and/or diastereoisomers.
  • Preferred compounds of the invention are optically active isomers.
  • preferred compounds of formula (I) containing only one chiral centre include an R enantiomer in substantially pure form, an S enantiomer in substantially pure form and enantiomeric mixtures which contain an excess of the R enantiomer or an excess of the S enantiomer.
  • the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • Said pharmaceutical composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention.
  • Preferred pharmaceutical compositions are sterile and pyrogen free.
  • compositions provided by the invention typically contain a compound of the invention which is a substantially pure optical isomer.
  • Compounds of formula (I) may be prepared by a sulfonylation reaction, for example the reaction of a secondary amine (II) which may or may not contain a defined stereochemical centre and a phenyl sulfonyl chloride (III), wherein R 1 to R 6 are as defined above (Scheme A).
  • reaction of the amine and the sulfonyl halide of formula (III), wherein X is a halogen such as chlorine, bromine of fluorine may be performed at room temperature in a suitable solvent, such as toluene or dichloromethane, in the presence of a base, for example triethylamine, JV- ethylmorpholine or diisopropylethylamine.
  • a suitable solvent such as toluene or dichloromethane
  • a base for example triethylamine, JV- ethylmorpholine or diisopropylethylamine.
  • Both the amine (II) and phenyl sulfonyl chloride (III) are either known compounds or could be prepared by the skilled person utilising known methods.
  • Compounds of formula (I) may be prepared by the reaction of a sulfonylated amine of formula (FV) with an alkylating agent of formula R 3 -Y, wherein R 1 to R 6 are as defined above and Y is a leaving group such as halogen, methanesulfonate orp- toluenesulfonate (Scheme B).
  • the reaction of the amine and the alkylating agent may be performed at room temperature in a suitable solvent, such as toluene or dichloromethane, in the presence of a base, for example triethylamine, N- ethylmorpholine or diisopropylethylamine.
  • Both the secondary amine (IV) and R 3 -Y are either known compounds or could be prepared by the skilled person utilising known methods.
  • Compounds of formula (I) may be prepared by the reaction of a sulfonylated amine of formula (FV) with an alcohol of formula R 3 -OH (Scheme C), wherein R 1 to R 6 are as defined above.
  • the reaction of the amine and the alcohol may be performed for example under Mitsunobu conditions (Jenkins, I. D. Mitsunobu, O, In Encyclopedia of Reagents for Org. Synthesis; Paquette, L. A., Ed.; Wiley: New York, 1995; Vol.
  • Compounds of formula (I) may be prepared by the reaction of a N-alkylated-S-aryl- thiohydroxylamine of formula (V) with a suitable oxidizing agent such as m- chloroperbenzoic acid (MCPBA), oxone, or a suitable peroxide-based reagent.
  • MCPBA m- chloroperbenzoic acid
  • oxone oxone
  • typical reaction conditions would include dehydrative reactions or conditions such as iodine in the presence OfPh 3 P, in a solvent such as dichloromethane, to form 1,3,4-oxadiazoles.
  • the ring closure reaction would typically take place by utilisation of Lawesson's reagent or P 2 S 5 , in a suitable solvent such as toluene or dioxan.
  • Compounds of formula (I), wherein A is a heterocycle as defined above, may be prepared by sulfonylation of an amine of general formula (IX), which is linked via a hydrazide to a solid phase resin.
  • the sulfonylation reaction proceeds as outlined in Scheme A, and is followed by a step which cleaves the hydrazide form the resin, with a strong acid such as CF 3 CO 2 H.
  • the resultant product of general formula (X) is acylated and converted for example into oxadiazole and thiadiazole derivatives of formula (I), via an intermediate of formula (VIII), as described in Scheme E above.
  • This reaction proceeds under a variety of conditions, including dehydrative coupling.
  • Alternative conditions include reaction of an ester, mixed anhydride or acid of general formula (VII) with the nucleophilic ethanolamine to provide the intermediate (XIII).
  • This intermediate is converted into an oxazole derivative of formula (I), initially by oxidation of the hydroxyl group to a ketone under standard conditions, for example utilising Dess-Martin Periodinane or pyridinium chlorochromate, followed by cyclisation to an oxazole under dehydrative conditions, for example using Burgess Reagent.
  • This procedure can also be adapted for the synthesis of thiazole derivatives, for example by employing methods, familiar to one skilled in the art as outlined, for example, in Joule, J.A. and Mills, K.A., Heterocyclic Chemistry (Fourth edition), 2000, Blackwell Science Ltd, Oxford, UK, ISBN 0-632-05453-0.
  • the thus obtained compounds of formula (I) may be salified by treatment with an appropriate acid or base. Racemic mixtures obtained by any of the above processes can be resolved by standard techniques, for example elution on a chiral chromatography column.
  • the compounds of the invention are found to be inhibitors of N-type calcium channels. Further, many preferred compounds of the invention exhibit selectivity over L-type calcium channels. The compounds of the invention are therefore therapeutically useful.
  • the compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • Preferred pharmaceutical compositions of the invention are compositions suitable for oral administration, for example tablets and capsules.
  • the compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
  • the compounds may also be administered as suppositories.
  • inhalation One route of administration is inhalation.
  • the major advantages of inhaled medications are their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route.
  • the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed.
  • compositions of the invention therefore include those suitable for inhalation.
  • the present invention also provides an inhalation device containing such a pharmaceutical composition.
  • said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out of the inhaler.
  • said propellant is a fluorocarbon.
  • Nebulizers are devices capable of delivering fine liquid mists of medication through a "mask" that fits over the nose and mouth, using air or oxygen under pressure. They are frequently used to treat those with asthma who cannot use an inhaler, including infants, young children and acutely ill patients of all ages.
  • Said inhalation device can also be, for example, a rotary inhaler or a dry powder inhaler, capable of delivering a compound of the invention without a propellant.
  • said inhalation device contains a spacer.
  • a spacer is a device which enables individuals to inhale a greater amount of medication directly into the lower airways, where it is intended to go, rather than into the throat. Many spacers fit on the end of an inhaler; for some, the canister of medication fits into the device. Spacers with withholding chambers and one-way valves prevent medication from escaping into the air. Many people, especially young children and the elderly, may have difficulties coordinating their inhalation with the action necessary to trigger a puff from a metered dose inhaler. For these patients, use of a spacer is particularly recommended.
  • nasal cavity's highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently, more so than drugs in tablet form.
  • Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients.
  • Drugs can be delivered nasally in smaller doses than medication delivered in tablet form. By this method absorption is very rapid and first pass metabolism is bypassed, thus reducing inter- patient variability.
  • Nasal delivery devices further allow medication to be administered in precise, metered doses.
  • the pharmaceutical compositions of the invention are typically suitable for intranasal administration. Further, the present invention also provides an intranasal device containing such a pharmaceutical composition.
  • a further route of administration is transdermal administration.
  • the present invention therefore also provides a transdermal patch containing a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • sublingual administration is also preferred.
  • the present invention therefore also provides a sub-lingual tablet comprising a compound of the invention or a pharmaceutically acceptable salt thereof.
  • a compound of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g.
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone
  • disaggregating agents e.g. starch, alginic acid, alginates or sodium starch glycolate
  • dyestuffs effervescing mixtures
  • dyestuffs effer
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • the compounds of the present invention are therapeutically useful in the treatment or prevention of conditions mediated by N-type calcium channels.
  • the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prevention of a condition mediated by N-type calcium channels. Also provided is a method of treating a patient suffering from or susceptible to a condition mediated by N-type calcium channels, which method comprises administering to said patient an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • These compounds are useful as calcium channel antagonists thereby inhibiting in a subject the onset of a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder.
  • N-type calcium channels are known to be closely involved in the mediation of pain transmission. Typically, the compounds of the invention are therefore used as analgesic agents. N-type calcium channels have been identified as being particularly important in the transmission of pain signals in the spinal cord (Chaplan S.R., Pogrel J 5 W., Yaksh TX. J. Pharm. Exp. Ther., 1994, 269, 1117-1123; Diaz, A., Dickenson, A.H. Pain, 1997, 69, 93-100).
  • the compounds of the invention are accordingly particularly effective in alleviating pain.
  • said medicament is for use in alleviating pain and said patient is suffering from or susceptible to pain.
  • the compounds of the invention are effective in alleviating both chronic and acute pain.
  • Acute pain is generally understood to be a constellation of unpleasant sensory, perceptual and emotional experiences of certain associate autonomic (reflex) responses, and of psychological and behavioural reactions provoked by injury or disease.
  • a discussion of acute pain can be found at Halpern (1984) Advances in Pain Research and Therapy, Vol.7, p.147.
  • Tissue injury provokes a series of noxious stimuli which are transduced by nociceptors to impulses transmitted to the spinal cord and then to the upper part of the nervous system.
  • Examples of acute pains which can be alleviated with the compounds of the invention include musculoskeletal pain, for example joint pain, lower back pain and neck pain, dental pain, post-operative pain, obstetric pain, for example labour pain, acute headache, neuralgia, myalgia, and visceral pain.
  • Chronic pain is generally understood to be pain that persists beyond the usual course of an acute disease or beyond a reasonable time for an injury to heal. A discussion of chronic pain can be found in the Halpern reference given above. Chronic pain is sometimes a result of persistent dysfunction of the nociceptive pain system.
  • Examples of chronic pains which can be alleviated with the compounds of the invention include trigeminal neuralgia, post-herpetic neuralgia (a form of chronic pain accompanied by skin changes in a dermatomal distribution following damage by acute Herpes Zoster disease), diabetic neuropathy, causalgia, "phantom limb” pain, pain associated with osteoarthritis, pain associated with rheumatoid arthritis, pain associated with cancer, pain associated with HIV, neuropathic pain, migraine and other conditions associated with chronic cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, spinal cord injury pain, central pain, post-herpetic pain, noncardiac chest pain, irritable bowel syndrome and pain associated with bowel disorders and dyspepsia.
  • trigeminal neuralgia a form of chronic pain accompanied by skin changes in a dermatomal distribution following damage by acute Herpes Zoster disease
  • diabetic neuropathy causalgia
  • neurogenic pain is pain caused by dysfunction of the peripheral or central nervous system in the absence of nociceptor stimulation by trauma or disease.
  • the compounds of the invention can, of course, be used to alleviate or reduce the incidence of neurogenic pain.
  • blockers of N-type calcium channels inhibit the release of excitatory amino acids, they can be used inter alia to inhibit damage to neuronal cells during anoxia, and function as neuroprotective agents, useful in the treatment of cerebral ischaemia or central nervous system injuries (Cox, B.; Denyer, J.C. Expert Opinion on Therapeutic Patents, 1998, 8, 1237-1250).
  • the compounds can also be utilised for the treatment of eye diseases (Chu, T-C; Potter, D.E. Research Communications in Pharmacology and Toxicology, 2001, 6, 263-275).
  • cerebral ischaemias which can be treated or prevented with the compounds of the invention include transient ischaemic attack, stroke, for example thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke or lacunar stroke, subarachnoid haemorrage, cerebral vasospasm, peri-natal asphyxia, drowning, cardiac arrest and subdural haematoma.
  • central nervous system injuries which can be treated with the compounds of the invention include traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injuries, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.
  • eye diseases which can be treated or prevented with the compounds of the invention include drug-induced optic neuritis, cataract, diabetic neuropathy, ischaemic retinopathy, retinal haemorrage, retinitis pigmentosa, acute glaucoma, in particular acute normal tension glaucoma, chronic glaucoma, in particular chronic normal tension glaucoma, macular degeneration, diabetic macular oedema, retinal artery occlusion and retinitis.
  • the compounds of the invention can be used in the treatment of seizure disorders.
  • seizure disorders which can be treated or prevented with the compounds of the invention include epilepsy and post-traumatic epilepsy, partial epilepsy (simple partial seizures, complex partial seizures, and partial seizures secondarily generalised seizures), generalised seizures, including generalised tonic/clonic seizures (grand mal), absence seizures (petit mal), myoclonic seizures, atonic seizures, clonic seizures, and tonic seizures, Lennox Gastaut, West Syndome (infantile spasms), multiresistant seizures and seizure prophylaxis (antiepileptogenic).
  • the compounds of the invention can also be utilised in the treatment of anxiety- related disorders and mood disorders, Bipolar disorder and post traumatic stress disorders.
  • the compounds of the invention can be utilised in the treatment of tinnitus, itch such as pruritoceptive, neuropathic, neurogenic and psychogenic itch, as well as urinary tract disorders such as urinary incontinence, and irritable bowel syndrome.
  • the compounds of the invention may also have application in disorders which are generally associated with blocking of L-type calcium channels, such as cardiovascular, antiasthmatic and antibronchoconstriction disorders for example in the prevention and treatment of disorders such as hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, premature labour, gastrointestinal motility disorders and cardiovascular disorders wherein the cardiovascular disorder is selected from the group consisting of hypertension, myocardial ischemia, angina, congestive heart failure, myocardial infarction and stroke.
  • the compounds of the invention can be utilised in the treatment of hypersensitivity disorders such as urinary tract disorders.
  • urinary tract disorders include, in particular, bladder dysfunctions such as overactive (or unstable) bladder (OAB), more specifically urinary incontinence, urgency, frequency, urge incontinence, nocturia; bladder hyper-reflexia; urinary tract inflammation specifically bladder inflammation e.g interstitial cystitis; and urinary tract infection.
  • OAB overactive (or unstable) bladder
  • the compounds of the invention may, where appropriate, be used prophylactically to reduce the incidence of such conditions.
  • the compounds of the invention can also be used in the treatment of lower urinary tract symptoms (LUTS).
  • LUTS comprises three groups of symptoms, which are irritative, which comprises urgency, frequency and nocturia and which can be associated with OAB and benign prostatic hyperplasia (BHP), obstructive and post micturition symptoms.
  • a therapeutically effective amount of a compound of the invention is administered to a patient.
  • a typical dose is from about 0.001 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration.
  • daily dosage levels are from 5 mg to
  • N-Methylglycine, ethyl ester hydrochloride (Sarcosine hydrochloride) (0.63 g, 4.09 mmol) and Et 3 N (1.15 mL, 8.18 mmol) were stirred vigorously in CH 2 Cl 2 (20 mL) and (2-chloro-4-trifluoromethylbenzenesulfonyl chloride (1.14 g, 4.09 mmol) was introduced.
  • Example 2 The following example was prepared by a modification of the method used for Example 1:
  • Step l (S)-2- [(2-Chloro-4-trifluoromethyl-benzenesulfonyl)methylamino]propionic acid (0.25 g, 0.72 mmol) and 2-amino-3-hydroxypyridine (0.08 g, 0.72 mmol) were dissolved in THF (20 mL) and EDC (0.139 g, 0.72 mmol) was introduced, followed by HOBT (0.098 g, 0.72 mmol) and N-ethylmorpholine (0.185 mL, 1.45 mmol). The reaction mixture was treated with EtOAc (20 mL), washed with 5% citric acid solution (20 mL) and sat. aqueous NaHCO 3 (20 mL).
  • Solid supported hydrazinecarboxylic acid ester (attached via ester group to resin) (0.864 g, 1.296 mmol) was suspended in dry dimethylformamide (DMF) (10 mL).
  • DMF dry dimethylformamide
  • HOBT 0.263 g, 1.944 mmol
  • 2-[(9H-fluoren-9-ylmethoxycarbonyl)-methyl-amino]-2-methyl- propionic acid FMOC-protected 2-methyl-2-methylaminopropionic acid; Fluka 29250) (0.683g, 1.944 mmol) and diisopropyl carbodiimide (0.864 g, 1.944 mmol) were introduced, and the suspension was shaken at ambient temperature for 20 h.
  • the resin sample was washed with DMF (3 x 20 mL), CH 3 OH (3 x 20 mL) and CH 2 Cl 2 (5 x 20 mL), and the resin was dried under vacuum for 2 h.
  • the resin was suspended in DMF (8 mL), piperidine (2 mL) was introduced and the suspension was shaken for 1 h. The resin was washed with DMF (6 x 20 mL), CH 3 OH (5 x 20 mL) and CH 2 Cl 2 (6 x 20 mL), and the resin was dried under vacuum for 18 h.
  • the resin-linked amino acid hydrazide was sulfonylated as follows: 2-chloro-4- trifluoromethyl-benzenesulfonyl chloride (0.542 g, 1.944 mmol) was dissolved in CH 2 Cl 2 (10 niL) and Et 3 N (0.27 mL, 1.944 mmol) was added.
  • the resin product was suspended in a mixture Of CH 2 Cl 2 (10 mL) and CF 3 CO 2 H (10 mL) and the suspension was shaken at ambient temperature for 1.5 h.
  • the resin was collected by filtration and washed with CH 2 Cl 2 (2 x 20 mL).
  • the combined filtrates were evaporated to dryness in vacuo, and the trifmoroacetic acid salt of 2-chloro-N-(l- hydrazinocarbonyl-l-methyl-ethyl)-N-methyl-4-trifluoromethylbenzenesulfonamide was purified by cation exchange chromatography utilising IST-MP-TsOH cartridges as follows. The residue was dissolved in CH 3 OH (3 mL) and acidified with acetic acid
  • Step 3 2-Chloro-N-(l -hydrazinocarbonyl- 1 -methylethyl)-N-methyl-4-trifluoromethylbenzene- sulfonamide (0.039 g, 0.105 mmol) and Et 3 N (0.021g, 0.21 mmol) in CH 2 Cl 2 (2 mL) was treated with 2,2-dimethylpropionyl chloride (pivaloyl chloride) (0.013 g, 0.105 mmol). Saturated NaHCO 3 solution (20 mL) was added, the organic layer was separated, washed with 5% aqueous citric acid solution (5mL) and dried (MgSO 4 ) before being evaporated to a residue.
  • Step 4 Polymer supported triphenylphosphine (0.4 g, 0.39 mmol) was suspended in CH 2 Cl 2 (5 mL) and iodine (0.099 g, 0.39 mmol) was added, and the reaction vessel was shaken vigorously for 1 h.
  • Et 3 N (0.11 mL, 0.78 mmol) and 2-chloro-N- ⁇ 2-[N'-(2,2-dimethyl- propionyl)hydrazino]-l,l-dimethyl-2-oxoethyl ⁇ -N-methyl-4-trifluoromethy-l-benzene- sulfonamide was introduced, and the reaction mixture was shaken for 18 h at ambient temperature.
  • reaction mixture was filtered, passed through a short column of florisil, evaporated and the residue was purified by preparative HPLC eluting with EtOAc/hexane (1:3), to provide N-[l-(5-tert-butyl-[l,3,4]oxadiazol-2-yl)-l-methyl- ethyl]-2-chloro-N-methyl-4-trifluoromethyl-benzenesulfonamide (0.012 g, 27% over 2 steps), retention time 4.16 min (HPLC System A); mass spectrum (ES+) m/z 412 (M + H).
  • Step 2 2-Chloro-N- ⁇ 1 -[N'-(2,2-dimethylpropionyl)hydrazinocarbonyl]- 1 -methylethyl ⁇ -N- methyl-4-trifluoromethylbenzenesulfonamide (0.65 g, 1.57 mmol) was dissolved in PhCH 3 (30 mL) and Lawesson's reagent (0.95 g, 2.35 mmol) was added. The suspension was heated at 100°C for 3 h. The toluene was removed in vacuo, and the residue was treated with EtOAc (40 mL), washed with water (40 mL). The organic layer was separated, dried (MgSO 4 ) and evaporated in vacuo.
  • Methyl-(3-phenyl-[ 1 ,2,4]oxadiazol-5-ylmethyl)amine (0.142 g, 0.075 mmol) was dissolved in dry CH 2 Cl 2 (1 mL) and Et 3 N (0.21 niL, 0.152 g, 1.5 mmol) was introduced, followed by a solution of (2-chloro-4-trifuoromethylbenzenesulfonyl chloride (0.23 g, 0.825 mmol) in dry CH 2 Cl 2 (1 mL).
  • Oxalyl chloride (2.9 mL, 4.21 g, 33.2 mmol) was added dropwise to a stirred solution of DMF (2.42 g, 33.2 mmol) in CH 3 CN (150 mL) at -5 0 C, and stirred at this temperature for a further 15 min.
  • Step 2 (S)-2-Chloro-N-(l-cyano-ethyl)-4-trifluoromethylbenzenesulfonamide (3.49 g, 11.2 mmol) in CH 3 OH (90 mL) was added to a solution of NH 2 OH.HC1 (3.88 g, 55.8 mmol) and Na 2 CO 3 (5.92 g, 55.8 mmol) in water (110 mL). The reaction mixture was heated at reflux for 18 h, cooled and concentrated in vacuo to an aqueous mixture, which was extracted with EtOAc (4 x 100 mL) and the combined extracts were dried (MgSO 4 ).
  • This compound was prepared by reaction of (S)-2-chloro-4-trifluoromethyl-N-[l-(5- trifluoromethyl-[l,2,4]oxadiazol-3-yl) ethyl]benzenesulfonamide (0.225 g, 0.531 mmol) under Mitsunobu conditions as described for Example 20, to provide (S)-2-chloro-N- isopropyl-4-trifluoromethyl-N-[l-(5-trifluoromethyl-[l,2,4]oxadiazol-3-yl)- ethyl]benzenesulfonamide (0.22 g, 95%).
  • Step 2 2-[(2-Chloro-4-trifluoromethylbenzenesulfonyl)methylamino]-N-(2-liydroxybutyl)- acetamide (0.33 g, 0.83 mmol) was dissolved in CH 2 Cl 2 (5 mL) and the solution was cooled in an ice bath. Dess-Martin Periodinane Reagent (2.5 mL, 0.875 mmol) was added dropwise with stirring, and the reaction mixture was stirred at ambient temperature for 60 h. Further CH 2 Cl 2 (20 mL) was added and the mixture was stirred vigorously with a mixture of 10% aqueous NaHCO 3 solution with a sodium sulphite solution present.
  • Step l n-Butyllithium (1.6M) (6.95 mL) was added to a solution of acetone oxime (0.41 g, 5.56 mmol) in dry THF (30 mL) and this mixture was stirred at 0 0 C for 1 h.
  • Step 2 (S)-2-Chloro-N-(4-hydroxyimino- 1 -methyl-2-oxo-pentyl)-N-methyl-4-trifluoromethyl- benzenesulfonamide (0.36 g, 0.89 mmol) was dissolved in a mixture Of CH 2 Cl 2 (5 mL) and Et 3 N (0.162 mL) and methanesulfonyl chloride (0.83 ⁇ L) was introduced at 0 0 C, and the reaction mixture was stirred at ambient temperature for 4 h. Further Et 3 N (1.3 equiv.) and methanesulfonyl chloride (1.2 equiv.) were added and stirring was continued for 18 h.
  • This compound was prepared by a sulfonylation procedure analogous to that utilised for Example 52.
  • the title compound was obtained (0.166 g, 58%); retention time 4.13 min (HPLC System B); mass spectrum (ES+) m/z 385 (M - H).
  • the human neuroblastoma cell line IMR32 has been used by a number of groups to investigate calcium ion channels either by electrophysiological or fluorescent techniques in low throughput assays (Carbone, E., et al. (1990) Pfl ⁇ gers Arch 416:170- 179; Rafferty, M., et al. (2000) Patent WO 00/06559; Seko, T., et al., (2001) Bioorg Med Chem Lett 11:2067-2070).
  • undifferentiated IMR32 cells constitutively express L-type calcium channels, whilst differentiated IMR32 cells express both N- and L-type channels. Therefore, undifferentiated IMR32 cells can be used to assay the L-type calcium channel and differentiated cells assayed in the presence of 5 ⁇ M nitrendipine can be used to study the N-type channels.
  • the Molecular Devices Corp FLEXstationTM was utilised to develop a medium throughput assay with undifferentiated and differentiated IMR32 cells labelled with Fluo-4. Opening of voltage-activated calcium channels was stimulated by depolarisation of cells with KCl, which was added by the FLEXstation' s fluidics system. The resulting influx of calcium into the cells was recorded by an increase in fluorescence. The assays were validated with known ion channel blockers.
  • IMR32 cells were grown in EMEM supplemented with 10% foetal bovine serum, 2 mM lutamine, 1% NEAA, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin. To differentiate the IMR32 cells, 1 mM dibutyryl cAMP and 2.5 ⁇ M bromodeoxyuridine were added to the cell culture media and cells maintained for 7-9 days.
  • HBSS Free cell dissociation buffer
  • the cells were then resuspended in assay buffer (HBSS containing Ca 2+ Mg 2+ and supplemented with 20 mM HEPES, pH 7.4) to give a total volume of 40 ml. 2 ⁇ M Fluo-4 and 50 ⁇ M probenecid were added and then the cells were incubated at 25 0 C for 30 min.
  • the cell pellet was resuspended in 40 ml assay buffer supplemented with 50 ⁇ M probenecid and incubated at 25 0 C for a further 30 min.
  • the cells were centrifuged as before and again resuspended in assay buffer supplemented with probenecid.
  • 200,000 cells were aliquoted into each well of a 96-well plate containing 0.001-100 ⁇ M compound to be tested (for the N-type assay 5 ⁇ M nitrendipine was also added to each well), in triplicate.
  • the final volume of compound and cells in assay buffer was 200 ⁇ l.
  • the plate containing cells was centrifuged at 300 rpm for 1 min with no brake in a Heraeus Labofuge 400E (rotor 8177).
  • the plate was then assayed using the FLEXstation (Molecular Devices Corp).
  • the excitation and emission wavelengths were 494 and 525 nm, respectively.
  • the calcium response was stimulated by the addition of 50 ⁇ l 250 niM KCl (50 mM final concentration) by the FLEXstation fluidics system.
  • SOFTmax Pro (Molecular Devices Corp) was used to calculate the change in fluorescence caused by calcium influx for each well and hence the IC 50 for each compound. The results are shown in the Table below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a remarqué que des composés représentés par la formule (I) ont un effet antagoniste sur les canaux calciques de type N. Dans la formule, A représente une fraction hétéroaryle ou hétérocyclyle de 5 à 10 chaînons, cette fraction étant éventuellement fusionnée à un phényle, un hétéroaryle à 5 ou 6 chaînons, un carbocyclyle C<sub
PCT/GB2005/003551 2004-09-14 2005-09-14 Sulfamides acycliques WO2006030211A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420424.4 2004-09-14
GB0420424A GB0420424D0 (en) 2004-09-14 2004-09-14 Therapeutic compounds

Publications (2)

Publication Number Publication Date
WO2006030211A2 true WO2006030211A2 (fr) 2006-03-23
WO2006030211A3 WO2006030211A3 (fr) 2006-06-01

Family

ID=33306547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003551 WO2006030211A2 (fr) 2004-09-14 2005-09-14 Sulfamides acycliques

Country Status (2)

Country Link
GB (1) GB0420424D0 (fr)
WO (1) WO2006030211A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118854A1 (fr) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94805A (en) * 1989-06-28 1994-04-12 Ciba Geigy Ag Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them
EP0775139A1 (fr) * 1994-08-10 1997-05-28 British Biotech Pharmaceuticals Limited Derives d'imidazopyridine utilises comme antagonistes du facteur d'activation plaquettaire (paf) et de la double histamine (h1)
EA002822B1 (ru) * 1997-12-17 2002-10-31 Мерк Энд Ко., Инк. Антагонисты рецептора интегрина
GB2352240A (en) * 1999-07-13 2001-01-24 Lilly Co Eli Novel sulphonamides useful in treating CNS disorders
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
WO2005068448A1 (fr) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides a action antagoniste sur des canaux calcium de type n

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9000174B2 (en) 2004-10-14 2015-04-07 Purdue Pharma L.P. 4-phenylsulfonamidopiperidines as calcium channel blockers
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (fr) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
US8642759B2 (en) 2008-05-06 2014-02-04 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline

Also Published As

Publication number Publication date
GB0420424D0 (en) 2004-10-20
WO2006030211A3 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2006030211A2 (fr) Sulfamides acycliques
CA2780772C (fr) Modulateurs selectifs du recepteur de sphingosine-1-phosphate et procedes de synthese chirale
RU2174979C2 (ru) Бифенилизоксазолсульфонамиды
US9447058B2 (en) Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
WO2005000309A2 (fr) Composes chimiques
JP2009538892A (ja) アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸
JP2009538891A (ja) Ｄｇａｔ１阻害剤としての１，３，４−オキサジアゾール誘導体
WO2005068448A1 (fr) Sulfonamides a action antagoniste sur des canaux calcium de type n
US20150259282A1 (en) Potassium Channel Blockers
AU2464301A (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
JP4769192B2 (ja) カテプシン阻害剤としての新規な化合物及び組成物
JP5947724B2 (ja) シクロフィリンの新しいインヒビター及びその使用
JP2010132590A (ja) オキサジアゾール化合物
JP2004535422A (ja) カテプシン阻害剤としての新しい化合物および組成物
AU2002305790A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin S inhibitors
US20110263580A1 (en) Method for treating alzheimer&#39;s disease and related conditions
WO2007007057A1 (fr) Antagonistes des canaux sodiques sns
US20040127426A1 (en) Peptidic compounds as cysteine protease inhibitors
MXPA06005528A (es) Tiazolidinona-amidas, amidas de acido tiazolidina-carboxilico, metodos de elaboracion, y uso de las mismas.
TW202239756A (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑硫羰基化合物及包含該等化合物之醫藥組合物
CN104159892A (zh) 被取代的苯基唑衍生物
US20030236288A1 (en) Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
RU2424239C2 (ru) Гетероциклические соединения и фармацевтические композиции как ингибиторы катепсина s
AU2015202660A1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
US20070043024A1 (en) Azacyclic compounds as inhibitors of sensory neurone specific channels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载